The signaling and functions of heterodimeric bone morphogenetic proteins

Cytokine and Growth Factor Reviews

Volumn 23, Issue 1-2, 2012, Pages 61-67

  Guo, Jing ^a   Wu, Gang ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Bone; Bone morphogenetic protein; Heterodimer; Heterodimeric; Homodimeric; Signaling

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 12; BONE MORPHOGENETIC PROTEIN 15; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 5; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN 9; BONE MORPHOGENETIC PROTEIN RECEPTOR 1; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; BONE MORPHOGENETIC PROTEIN RECEPTOR 1B; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CHORDIN; GROWTH DIFFERENTIATION FACTOR 10; GROWTH DIFFERENTIATION FACTOR 3; GROWTH DIFFERENTIATION FACTOR 6; GROWTH DIFFERENTIATION FACTOR 9; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOSTATIN; NOGGIN; OSTEOGENIC PROTEIN 1; OSTEOGENIN; PROCOLLAGEN C PROTEINASE; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RUNX2;

BONE DEFECT; BONE DEVELOPMENT; BONE GRAFT; CHONDROGENESIS; DROSOPHILA; EMBRYO DEVELOPMENT; HUMAN; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; ORGANOGENESIS; OSSIFICATION; OSTEOBLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; SHORT SURVEY; SIGNAL TRANSDUCTION; ZEBRA FISH;

ANIMALS; BONE MORPHOGENETIC PROTEINS; DROSOPHILA; EMBRYO, NONMAMMALIAN; EMBRYONIC DEVELOPMENT; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEUROGENESIS; OSTEOGENESIS; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION;

EID: 84858332746     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2012.02.001     Document Type: Short Survey

References (73)

1. Urist M.R. Bone: formation by autoinduction. Science 1965, 150:893-899.
2. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., et al. Novel regulators of bone formation: molecular clones and activities. Science 1988, 242:1528-1534.
3. Reddi A.H., Reddi A. Bone morphogenetic proteins (BMPs): from morphogens to metabologens. Cytokine Growth Factor Rev 2009, 20:341-342.
4. Ducy P., Karsenty G. The family of bone morphogenetic proteins. Kidney Int 2000, 57:2207-2214.
5. Reddi A.H. BMPs: from bone morphogenetic proteins to body morphogenetic proteins. Cytokine Growth Factor Rev 2005, 16:249-250.
6. Bessa P.C., Casal M., Reis R.L. Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic. Part I (basic concepts). J Tissue Eng Regen Med 2008, 2:1-13.
7. Liao W.X., Moore R.K., Otsuka F., Shimasaki S. Effect of intracellular interactions on the processing and secretion of bone morphogenetic protein-15 (BMP-15) and growth and differentiation factor-9. Implication of the aberrant ovarian phenotype of BMP-15 mutant sheep. J Biol Chem 2003, 278:3713-3719.
8. Sieber C., Kopf J., Hiepen C., Knaus P. Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev 2009, 20:343-355.
9. Wang E.A., Rosen V., Cordes P., Hewick R.M., Kriz M.J., Luxenberg D.P., et al. Purification and characterization of other distinct bone-inducing factors. Proc Natl Acad Sci USA 1988, 85:9484-9488.
10. Ozkaynak E., Rueger D.C., Drier E.A., Corbett C., Ridge R.J., Sampath T.K., et al. OP-1 cDNA encodes an osteogenic protein in the TGF-beta family. EMBO J 1990, 9:2085-2093.
11. Sampath T.K., Coughlin J.E., Whetstone R.M., Banach D., Corbett C., Ridge R.J., et al. Bovine osteogenic protein is composed of dimers of OP-1 and BMP-2A, two members of the transforming growth factor-beta superfamily. J Biol Chem 1990, 265:13198-13205.
12. D'Alessandro J.S., Yetz-Aldape J., Wang E.A. Bone morphogenetic proteins induce differentiation in astrocyte lineage cells. Growth Factors 1994, 11:53-69.
13. Hazama M., Aono A., Ueno N., Fujisawa Y. Efficient expression of a heterodimer of bone morphogenetic protein subunits using a baculovirus expression system. Biochem Biophys Res Commun 1995, 209:859-866.
14. Aono A., Hazama M., Notoya K., Taketomi S., Yamasaki H., Tsukuda R., et al. Potent ectopic bone-inducing activity of bone morphogenetic protein-4/7 heterodimer. Biochem Biophys Res Commun 1995, 210:670-677.
15. Israel D.I., Nove J., Kerns K.M., Kaufman R.J., Rosen V., Cox K.A., et al. Heterodimeric bone morphogenetic proteins show enhanced activity in vitro and in vivo. Growth Factors 1996, 13:291-300.
16. Zhao M., Zhao Z., Koh J.T., Jin T.C., Franceschi R.T. Combinatorial gene therapy for bone regeneration: cooperative interactions between adenovirus vectors expressing bone morphogenetic proteins 2, 4, and 7. J Cell Biochem 2005, 95:1-16.
17. Zheng Y., Wu G., Zhao J., Wang L., Sun P., Gu Z. rhBMP2/7 heterodimer: an osteoblastogenesis inducer of not higher potency but lower effective concentration compared with rhBMP2 and rhBMP7 homodimers. Tissue Eng A 2010, 16:879-887.
18. Valera E., Isaacs M.J., Kawakami Y., Izpisua Belmonte J.C., Choe S. BMP-2/6 heterodimer is more effective than BMP-2 or BMP-6 homodimers as inductor of differentiation of human embryonic stem cells. PLoS One 2010, 5:e11167.
19. Butler S.J., Dodd J. A role for BMP heterodimers in roof plate-mediated repulsion of commissural axons. Neuron 2003, 38:389-401.
20. Zhu W., Boachie-Adjei O., Rawlins B., Crystal R.G., Hidaka C. A BMP2/7 fusion gene enhances osteoblastic differentiation in mesenchymal cells. Mol Ther 2004, 9:S338.
21. Isaacs M.J., Kawakami Y., Allendorph G.P., Yoon B.H., Belmonte J.C., Choe S. Bone morphogenetic protein-2 and -6 heterodimer illustrates the nature of ligand-receptor assembly. Mol Endocrinol 2010, 24:1469-1477.
22. Zhu W., Rawlins B.A., Boachie-Adjei O., Myers E.R., Arimizu J., Choi E., et al. Combined bone morphogenetic protein-2 and -7 gene transfer enhances osteoblastic differentiation and spine fusion in a rodent model. J Bone Miner Res 2004, 19:2021-2032.
23. Pan Q., Yang S., Sun F. Expression of BMP-2/7 heterodimers with potent ability to stimulate osteogenic differentiation in CHO cells. Sheng Wu Gong Cheng Xue Bao 2008, 24:473-479.
24. Pan Q., Yang S., Dong Q., Sun F. Relationship between the bioactivity of BMP2/7 heterodimers and its regulation of CIZ expression. China Biotechnol 2007, 27:14-18.
25. Chen D., Zhao M., Mundy G.R. Bone morphogenetic proteins. Growth Factors 2004, 22:233-241.
26. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
27. Lavery K., Swain P., Falb D., Alaoui-Ismaili M.H. BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. J Biol Chem 2008, 283:20948-20958.
28. Miyazono K., Kamiya Y., Morikawa M. Bone morphogenetic protein receptors and signal transduction. J Biochem 2010, 147:35-51.
29. Miyazono K. Signal transduction by bone morphogenetic protein receptors: functional roles of Smad proteins. Bone 1999, 25:91-93.
30. 2-terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation. J Bone Miner Res 2003, 18:2060-2068.
31. Massague J. Integration of Smad and MAPK pathways: a link and a linker revisited. Genes Dev 2003, 17:2993-2997.
32. Hoffmann A., Preobrazhenska O., Wodarczyk C., Medler Y., Winkel A., Shahab S., et al. Transforming growth factor-beta-activated kinase-1 (TAK1), a MAP3K, interacts with Smad proteins and interferes with osteogenesis in murine mesenchymal progenitors. J Biol Chem 2005, 280:27271-27283.
33. Ehrlich M., Horbelt D., Marom B., Knaus P., Henis Y.I. Homomeric and heteromeric complexes among TGF-beta and BMP receptors and their roles in signaling. Cell Signal 2011, 23:1424-1432.
34. Bragdon B., Moseychuk O., Saldanha S., King D., Julian J., Nohe A. Bone morphogenetic proteins: a critical review. Cell Signal 2011, 23:609-620.
35. Kirsch T., Nickel J., Sebald W. BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II. EMBO J 2000, 19:3314-3324.
36. Sebald W., Nickel J., Zhang J.L., Mueller T.D. Molecular recognition in bone morphogenetic protein (BMP)/receptor interaction. Biol Chem 2004, 385:697-710.
37. Allendorph G.P., Isaacs M.J., Kawakami Y., Izpisua Belmonte J.C., Choe S. BMP-3 and BMP-6 structures illuminate the nature of binding specificity with receptors. Biochemistry 2007, 46:12238-12247.
38. Saremba S., Nickel J., Seher A., Kotzsch A., Sebald W., Mueller T.D. Type I receptor binding of bone morphogenetic protein 6 is dependent on N-glycosylation of the ligand. FEBS J 2008, 275:172-183.
39. Koh J.T., Zhao Z., Wang Z., Lewis I.S., Krebsbach P.H., Franceschi R.T. Combinatorial gene therapy with BMP2/7 enhances cranial bone regeneration. J Dent Res 2008, 87:845-849.
40. Buijs J.T., van der Horst G., van den Hoogen C., Cheung H., de Rooij B., Kroon J., et al. The BMP2/7 heterodimer inhibits the human breast cancer stem cell subpopulation and bone metastases formation. Oncogene 2011, 10.1038/onc.2011.400.
41. Nohe A., Hassel S., Ehrlich M., Neubauer F., Sebald W., Henis Y.I., et al. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem 2002, 277:5330-5338.
42. Nohe A., Keating E., Underhill T.M., Knaus P., Petersen N.O. Effect of the distribution and clustering of the type I A BMP receptor (ALK3) with the type II BMP receptor on the activation of signalling pathways. J Cell Sci 2003, 116:3277-3284.
43. Heinecke K., Seher A., Schmitz W., Mueller T.D., Sebald W., Nickel J. Receptor oligomerization and beyond: a case study in bone morphogenetic proteins. BMC Biol 2009, 7:59.
44. Eivers E., Demagny H., De Robertis E.M. Integration of BMP and Wnt signaling via vertebrate Smad1/5/8 and Drosophila Mad. Cytokine Growth Factor Rev 2009, 20:357-365.
45. Groppe J., Greenwald J., Wiater E., Rodriguez-Leon J., Economides A.N., Kwiatkowski W., et al. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 2002, 420:636-642.
46. Walsh D.W., Godson C., Brazil D.P., Martin F. Extracellular BMP-antagonist regulation in development and disease: tied up in knots. Trends Cell Biol 2010, 20:244-256.
47. Zhu W., Kim J., Cheng C., Rawlins B.A., Boachie-Adjei O., Crystal R.G., et al. Noggin regulation of bone morphogenetic protein (BMP) 2/7 heterodimer activity in vitro. Bone 2006, 39:61-71.
48. Piccolo S., Sasai Y., Lu B., De Robertis E.M. Dorsoventral patterning in Xenopus: inhibition of ventral signals by direct binding of chordin to BMP-4. Cell 1996, 86:589-598.
49. Shen Z.J., Nakamoto T., Tsuji K., Nifuji A., Miyazono K., Komori T., et al. Negative regulation of bone morphogenetic protein/Smad signaling by Cas-interacting zinc finger protein in osteoblasts. J Biol Chem 2002, 277:29840-29846.
50. Graff J.M., Thies R.S., Song J.J., Celeste A.J., Melton D.A. Studies with a Xenopus BMP receptor suggest that ventral mesoderm-inducing signals override dorsal signals in vivo. Cell 1994, 79:169-179.
51. Macias-Silva M., Hoodless P.A., Tang S.J., Buchwald M., Wrana J.L. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2. J Biol Chem 1998, 273:25628-25636.
52. Little S.C., Mullins M.C. Bone morphogenetic protein heterodimers assemble heteromeric type I receptor complexes to pattern the dorsoventral axis. Nat Cell Biol 2009, 11:637-643.
53. O'Connor M.B., Umulis D., Othmer H.G., Blair S.S. Shaping BMP morphogen gradients in the Drosophila embryo and pupal wing. Development 2006, 133:183-193.
54. Newfeld S.J., Wisotzkey R.G., Kumar S. Molecular evolution of a developmental pathway: phylogenetic analyses of transforming growth factor-beta family ligands, receptors and Smad signal transducers. Genetics 1999, 152:783-795.
55. Parker L., Stathakis D.G., Arora K. Regulation of BMP and activin signaling in Drosophila. Prog Mol Subcell Biol 2004, 34:73-101.
56. Shimmi O., Umulis D., Othmer H., O'Connor M.B. Facilitated transport of a Dpp/Scw heterodimer by Sog/Tsg leads to robust patterning of the Drosophila blastoderm embryo. Cell 2005, 120:873-886.
57. Claffey N., Clarke E., Polyzois I., Renvert S. Surgical treatment of peri-implantitis. J Clin Periodontol 2008, 35:316-332.
58. Saito N., Takaoka K. New synthetic biodegradable polymers as BMP carriers for bone tissue engineering. Biomaterials 2003, 24:2287-2293.
59. Kretlow J.D., Mikos A.G. Review: mineralization of synthetic polymer scaffolds for bone tissue engineering. Tissue Eng 2007, 13:927-938.
60. Silber J.S., Anderson D.G., Daffner S.D., Brislin B.T., Leland J.M., Hilibrand A.S., et al. Donor site morbidity after anterior iliac crest bone harvest for single-level anterior cervical discectomy and fusion. Spine 2003, 28:134-139.
61. Heary R.F., Schlenk R.P., Sacchieri T.A., Barone D., Brotea C. Persistent iliac crest donor site pain: independent outcome assessment. Neurosurgery 2002, 50:510-516. discussion 6-7.
62. Smith J.D., Abramson M. Membranous vs endochondrial bone autografts. Arch Otolaryngol 1974, 99:203-205.
63. Asamura S., Ikada Y., Matsunaga K., Wada M., Isogai N. Treatment of orbital floor fracture using a periosteum-polymer complex. J Craniomaxillofac Surg 2010, 38:197-203.
64. Carson J.S., Bostrom M.P. Synthetic bone scaffolds and fracture repair. Injury 2007, 38(Suppl. 1):S33-S37.
65. Sokolsky-Papkov M., Agashi K., Olaye A., Shakesheff K., Domb A.J. Polymer carriers for drug delivery in tissue engineering. Adv Drug Deliv Rev 2007, 59:187-206.
66. Boden S.D., Kang J., Sandhu H., Heller J.G. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine 2002, 27:2662-2673.
67. Zara J.N., Siu R.K., Zhang X., Shen J., Ngo R., Lee M., et al. High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo. Tissue Eng A 2011, 17:1389-1399.
68. Kaneko H., Arakawa T., Mano H., Kaneda T., Ogasawara A., Nakagawa M., et al. Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone 2000, 27:479-486.
69. Uludag H., D'Augusta D., Palmer R., Timony G., Wozney J. Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model. J Biomed Mater Res 1999, 46:193-202.
70. Carpenter R.S., Goodrich L.R., Frisbie D.D., Kisiday J.D., Carbone B., McIlwraith C.W., et al. Osteoblastic differentiation of human and equine adult bone marrow-derived mesenchymal stem cells when BMP-2 or BMP-7 homodimer genetic modification is compared to BMP-2/7 heterodimer genetic modification in the presence and absence of dexamethasone. J Orthop Res 2010, 28:1330-1337.
71. Zheng Y., Wang L., Zhang X., Gu Z., Wu G. BMP2/7 heterodimer can modulate all cellular events of the in vitro RANKL-mediated osteoclastogenesis respectively in different dose-patterns. Tissue Eng A 2012, 18(5-6):621-630.
72. Wang J., Zheng Y., Zhao J., Liu T., Gao L., Gu Z., et al. Low-dose rhBMP2/7 heterodimer to reconstruct peri-implant bone defects: a micro-CT evaluation. J Clin Periodontol 2012, 39:98-105.
73. Alarmo E.L., Kallioniemi A. Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis?. Endocr Relat Cancer 2010, 17:R123-R139.